A 40-foot container arrived at the Port of Rotterdam carrying 2,400 units of a Class IIa diagnostic imaging device from Shanghai. The CE certification was valid, the technical file complete. What failed was the Dutch Instructions for Use.
The original Chinese read: “The device should be operated by trained medical personnel in a dry environment.” The in-house Dutch translation used a colloquial word for “dry” that the Dutch health authority (IGJ) did not recognize as equivalent to the specific humidity range in the device’s risk management file—required under MDR 2017/745 electromagnetic compatibility guidance.
Result: 2,400 units held at customs for 11 weeks. Total cost: €380,000. The distributor lost two of three hospital contracts to a competitor.
Three Jurisdictions, Three Sets of Rules
The EU under MDR 2017/745 mandates IFU and labeling in all official languages of Member States where the device is sold—up to 24 languages. Under Article 10(11), the IFU must be “clear and understandable.” Notified bodies evaluate translation quality, not just its existence.
The US FDA requires all labels and labeling in English under 21 CFR Part 801. Spanish-language IFU unlocks access to the $800 billion US Hispanic healthcare market without regulatory friction.
China’s NMPA mandates simplified Chinese documentation for all imported devices, with terminology conforming to NMPA’s published nomenclature standards. The distinction between simplified and traditional Chinese creates additional complexity for manufacturers targeting multiple Asian markets.
Why Device Classification Determines Translation Strategy
| Device Class | CE (EU) | FDA (US) | NMPA (China) | Translation Risk |
|---|---|---|---|---|
| Class I | Self-declaration | General controls | Chinese docs mandatory | Low |
| Class IIa | Notified body review | 510(k) pathway | Clinical evaluation in Chinese | Medium |
| Class IIb | Extensive technical file | Clinical data required | Full Chinese documentation | High |
| Class III | Design dossier mandatory | PMA pathway | Most complex registration | Critical |
A 2024 RAPS survey found 68% of international medical device manufacturers experienced regulatory delays from translation issues. For Class III manufacturers, that figure reached 84%. Terminology inconsistency (47%) and regulatory terminology mismatches (39%) topped the list.
Three Ways Translation Fails
Terminology inconsistency. Using “sample” in one section and “specimen” in another—synonyms in English, potentially distinct terms under regulatory frameworks. Multiply this across 24 EU languages, and minor inconsistencies become contradictions that flagged by notified bodies.
Regulatory terminology mismatches. A linguistically fluent translator selects a target term that is technically accurate but does not match what the receiving authority expects. This requires translators with regulatory background—MDR guidance, FDA 21 CFR, and NMPA nomenclature—not just native speakers.
Contextual errors. “Hospital-grade outlet” has a specific NEMA meaning under US electrical code that has no equivalent in other countries’ standards. A direct translation produces an instruction that is technically meaningless or misleading.
CE Marking and Translation Non-Conformity
Under MDR, notified bodies now conduct detailed translation quality reviews, especially for non-EU manufacturers with Chinese, Japanese, or Korean source documentation. Translation-related non-conformities accounted for 12% of all adverse findings in EU medical device conformity assessments in 2024. For non-EU manufacturers: 23%—nearly one in four.
The EU’s EUDAMED database recorded a 19% increase in translation-related adverse event reports in 2024 year-over-year.
The Cost of Getting It Right
Specialist medical device translation for a Class IIa IFU costs $3,000–$8,000 per language. Five-market EU entry: $15,000–$40,000.
A translation-triggered CE certification rejection costs $50,000–$200,000. A customs hold runs $3,000–$15,000 per week. Precision translation is not a cost center—it is insurance against failures an order of magnitude larger.
Artlangs Translation delivers CE/FDA/NMPA-compliant medical device translation across 230+ language pairs, combining regulatory expertise with linguistic precision. We maintain terminology management systems for device portfolios spanning decades of regulatory history—IFU, technical documentation, and labeling that meet each jurisdiction’s exact requirements. Our capabilities extend to video localization and subtitle translation for device launches, short-form content and drama localization for health communication, game localization for medical training, multilingual audiobook and dubbing for clinical education, and large-scale multilingual data annotation for AI-assisted diagnostic development. Quality at every layer of the medical technology ecosystem—that is our standard.
Artlangs Translation — Specialist Medical Device Translation Services | CE/FDA/NMPA Compliant | 230+ Language Pairs
